37 research outputs found
Case Report: Soft Tissue Metastasis from Immature Teratoma of the Testis: Second Case Report and Review of the Literature
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as first-line treatment in HER2-negative advanced gastric cancer.
Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer.
The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment
We aimed to investigate the prognostic significance of neutrophil, lymphocyte, platelet, mean platelet value (MPV), platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR) in patients with locally advanced gastric cancer (LAGC). One hundred sixty-eight patients with LAGC who had been followed-up between 2004 and 2008 were included in present study. The results of hematological (platelet, lymphocyte, neutrophil and MPV) and biochemical (uric acid and LDH) parameters were evaluated before treatment. NLR was divided into two groups as 160. Platelet counts and lymphocyte counts were also divided into two groups; a parts per thousand currency sign300.000/mm3 and > 300.000/mm3, and < 1,500/mm3 and a parts per thousand yen1,500/mm3, respectively. Results were evaluated with Kaplan-Meier and Long-rank tests. The mean age of patients at diagnosis was 60.1 +/- A 12.1 and 114 of patients (67.8%) were male. For 168 patients, 48 months overall survival (OS) rate was 45.2% and the median OS was 39 months (range 33-44). In patients whose PLR was less than 160 (n = 54), the median OS was 45 months (range 38-52) and also for cases whose PRL was greater than 160 (n = 114), the median OS was 27 months (range 22-32) (p = 0.006). While for fifty patients whose lymphocyte counts were less than 1,500, the median OS was 27 months (range 21-33), in cases with high lymphocyte counts (a parts per thousand yen1,500) (n = 118), it was 41 months (range 35-48) (p = 0.03). The median OS was 41 (range 34-48) and 30 (range 23-37) months in two platelets groups, respectively (p = 0.24). However, in the patients whose NLR was less than 2.56 (n = 107), median OS was better than with cases whose NLR was greater than or equal to 2.56 (42 vs. 27 months). Routine peripheral blood counts may be useful prognostic factor for evaluating the accuracy of risk stratification in patients with radically resected gastric cancer Our results need to be confirmed by study including larger sample size in future
Determining of metastatic lymph node ratio in patients who underwent D2 dissection for gastric cancer
The purpose of this study was to determine outcome of the ratio of metastatic lymph nodes to the total number of dissected lymph nodes (MLR) in patients with gastric cancer. We retrospectively analyzed 111 patients who underwent D-2 lymph node dissection. The prognostic factors including UICC/AJCC TNM classification and MLR were evaluated by univariate and multivariate analysis. The MLR was significantly higher in patients with a larger tumor, lymphatic vessel invasion, blood vessel invasion and perineural invasion, and advanced stage. Moreover, the MLR was significantly associated with the depth of invasion and the number of lymph node metastasis. The univariate analysis revealed for overall survival (OS) that stage of disease, lymphatic vessel invasion, blood vessel invasion, perineural invasion, lymph node metastasis (UICC/AJCC pN stage) and MLR were relevant prognostic indicators. Furthermore, both UICC/AJCC pN stage and MLR were detected as prognostic factor by multivariate analysis, as was perineural invasion. Our results indicated that MLR and UICC/AJCC pN staging system were important prognostic factors for OS of patients with D-2 lymph node dissection in gastric cancer in a multivariate analysis. MLR may be useful for evaluating the status of lymph node metastasis in gastric cancer
Kadınlarda Küçük Hücreli Dışı Akciğer Kanseri: Farklı Bir Antite mi?
Non-Small Cell Lung Cancer in Women: A Distinct Entity?Kadınlarda Küçük Hücreli Dışı Akciğer Kanseri: Farklı Bir Antite mi?Umut Kefeli1, Bala Basak Oven Ustaalioglu2, Burcak Yilmaz2, Dincer Aydin3, Nur Sener3, Mehmet Aliustaoglu3Mahmut GumusAmaç: Akciğer kanseri her iki cinsiyette de kanser ile ilişkili önde gelen ölümnedenlerinden biridir ve tüm dünyada giderek artmaktadır. Birçok çalışmadainsidans ve mortalitedeki bu artış cinsiyet, tümör tipi ve hastaların klinikkarakteristikleri ile ilişkili bulunmuştur. Bu çalışmanın amacı kadın küçükhücreli dışı akciğer kanserli (KHDAK) hastalarda klinik özellik farklılıklarını veprognostik faktörleri araştırmaktır.Gereç ve Yöntem: 2005-2012 yılları arasında 893 KHDAK’lı hastanın verilerigeriye yönelik incelendi. Hastaların 773’ü erkek (%86.5) ve 120’si (%13.5)kadındı. Hastaların demografik verileri, histolojik tipleri, klinik evreleri,semptomları ve tedavi modaliteleri incelendi. Sağkalım Kaplan-Meier metoduve prognostik faktörler log-rank ve Cox regresyon testleri ile analiz edildi.Bulgular: Kadın hastaların medyan yaşı 60.6 idi. Erkek hastalarda sigaraöyküsü olanların oranı % 89.6 iken, kadın hastalarda bu oran % 44.9 olarakbulundu. Kadınlarda en sık tümör tipi adenokarsinom (%32.7),erkeklerdeskuamöz hücreli karsinomdu (%34.0). Kadın hastaların medyan genelsağkalımı 13.7 ay, erkek hastaların 10.9 ay olarak saptandı (p>0.05). Tekdeğişkenli analizlerde kadın hastalarda yaş, kilo kaybı, kombinasyon tedavisive performans statüsü sağkalımı artıran faktörlerdi. Çok değişkenlianalizlerde kadın hastalarda sağkalım ile ilşkili tek faktör iyi performansstatüsüydü.Sonuç: Kadınlarda KHDAK erkeklere göre farklıdır. Kadınlarda adenokarsinomdaha sıktır ve KHDAK daha iyi prognozludur. Kadın KHDAK’nin daha detaylıanlaşılması yeni tedavi ve prevensiyon stratejelerinin geliştirilmesine olanaksağlayacaktır.Anahtar Sözcükler: Cinsiyet, akciğer kanseri, kadınABSTRACTAim: Lung cancer is one oKey Words: Sex, lung canNon-Small Cell Lung Cancer in Women: A Distinct Entity?Kadınlarda Küçük Hücreli Dışı Akciğer Kanseri: Farklı Bir Antite mi?Umut Kefeli1, Bala Basak Oven Ustaalioglu2, Burcak Yilmaz2, Dincer Aydin3, Nur Sener3, Mehmet Aliustaoglu3Mahmut GumusABSTRACTAim: Lung cancer is one of the major causes of cancer-related deaths in bothsexes and increasing worldwide. In many studies this increase in incidenceand mortality was related to the sex, tumor type and clinical characteristicsof the patients. The aim of this study was to evaluate the differences inclinical features and the prognostic factors in our female patients withNSCLC.Methods: We retrospectively analyzed the records of our 893 patients withnon-small cell lung cancer (NSCLC) from 2005 to 2012. Of these, 773 weremale (86.5%) and 120 were female (13.5%) patients. The data includeddemographic information, histologic classification, clinical staging, presentingsymptoms and treatment modalities. Survival was estimated by usingKaplan–Meier method and prognostic factors were evaluated with log-rankand Cox regression tests.Results: The median age of the female patients was 60.6. The percent of themale and female patients that had a smoking history was 89.6% and 44.9%,respectively. Most common tumor type in female patients wasadenocarcinoma (32.7%) and in male patients was squamos cell carcinoma(34.0%). The median survival time for female patients was 13.7 months andfor the male patients it was 10.9 months (p>0.05). In univariate analysis, age,weight loss, combination therapy and PS correlated with a better OS forfemale patients. In multivariate analysis, only good PS showed consistencywith survival for women.Conclusion: NSCLC in women is different in women as compared with men.Women are more likely to develop adenocarcinoma of the lung and havemore favorable prognosis. A more through understanding of the NSCLC inwomen may lead to new treatment and prevention strategies.Key Words: Sex, lung cancer, women</div